Probiotics, secretory IgA and inflammation

Patent metadata

Field	Value
Publication number	US-10501530-B2
Application number	US-201715787904-A
Country	US
Kind code	B2
Filing date	Oct 19, 2017
Priority date	Jun 24, 2008
Publication date	Dec 10, 2019
Grant date	Dec 10, 2019

Abstract

Probiotics and ways to increase their effectiveness are provided. One embodiment of the present invention relates to a combination of probiotics with SIgA and possible uses of this combination. For example a use of a composition comprising SIgA and at least one probiotic for the preparation of a product to treat or prevent inflammation is disclosed.

First claim

The invention is claimed as follows:

1. A method for reducing the severity of an inflammatory condition selected from the group consisting of inflammatory bowel disease, Crohn's disease, ulcerative colitis, necrotizing enterocolitis, eczema, allergy, and atopy, the method comprising:
administering a therapeutically-effective amount of a composition comprising isolated secretory immunoglobulin A (SIgA) and a probiotic micro-organism to a subject, wherein the isolated SIgA and the probiotic micro-organism are present in the form of a complex with each other, the isolated SIgA and the probiotic micro-organism are present in the composition in a stoichiometric ratio of a least 10:1, and the composition comprises between 10 2 and 2×10 7 cells of the probiotic micro-organism per daily dose.

2. The method of claim 1 , wherein the subject is selected from the group consisting of newborns, infants, juveniles, adults, elderly, and mothers during pregnancy or lactation.

3. The method of claim 1 , wherein the composition comprises milk obtained from an animal or plant source.

4. The method of claim 3 , wherein the milk is selected from the group consisting of cows' milk, human milk, sheep milk, goat milk, horse milk, camel milk, rice milk, and soy milk.

5. The method of claim 1 , wherein the composition comprises milk protein fractions or colostrum.

6. The method of claim 1 , wherein the composition contains a prebiotic.

7. The method of claim 6 , wherein the prebiotic is selected from the group consisting of oligosaccharides, dietary fibers, and mixtures thereof.

8. The method of claim 6 , wherein the prebiotic is selected from the group consisting of fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS), isomalto-oligosaccharides, xylo-oligosaccharides, oligosaccharides of soy, glycosyl sucrose (GS), lactosucrose (LS), lactulose (LA), palatinose-oligosaccharides (PAO), maltooligosaccharides, pectins, hydrolysates thereof, and mixtures thereof.

9. The method of claim 1 , wherein the composition comprises between 10 2 and 10 10 cells of the probiotic micro-organism per daily dose.

10. The method of claim 1 , wherein the composition comprises between 0.0001 mg SIgA and 10 mg SIgA per daily dose.

11. The method of claim 1 , wherein the probiotic micro-organism is selected from the group consisting of Bifidobacterium, Lactobacillus, Streptococcus, Saccharomyces, and mixtures thereof.

12. The method of claim 1 , wherein the probiotic micro-organism is selected from the group consisting of Bifidobacterium longum, Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus salivarius, Enterococcus faecium, Saccharomyces boulardii and Lactobacillus reuteri, and mixtures thereof.

13. The method of claim 1 , wherein the probiotic micro-organism is selected from the group consisting of Lactobacillus johnsonii (NCC533; CNCM I-1225), Bifidobacterium longum (NCC490; CNCM I-2170), Bifidobacterium longum (NCC2705; CNCM I-2618), Bifidobacterium lactis (2818; CNCM I-3446), Lactobacillus paracasei (NCC2461: CNCM 1-2116), Lactobacillus rhamnosus GG (ATCC53103), Lactobacillus rhamnosus (NCC4007; CGMCC 1.3724), Enterococcus faecium SF 68 (NCIMB10415), and mixtures thereof.

14. The method of claim 1 , wherein at least 90% of the probiotic micro-organism present in the composition is associated with at least one isolated SIgA molecule as immune complexes.

15. The method of claim 1 , wherein the isolated SIgA and the probiotic micro-organism are present in the composition in a stoichiometric ratio of at least 100:1.

Assignees

• Nestec Sa
• Nestle Sa

Inventors

• Benyacoub Jalil
• Corthesy Blaise
• Blum-Sperisen Stephanie
• Favre Laurent

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title